Free Trial
NASDAQ:ALLK

Allakos (ALLK) Stock Price, News & Analysis

Allakos logo
$0.33 0.00 (0.00%)
As of 05/15/2025

About Allakos Stock (NASDAQ:ALLK)

Key Stats

Today's Range
$0.33
$0.33
50-Day Range
$0.33
$0.33
52-Week Range
$0.22
$1.56
Volume
N/A
Average Volume
1.22 million shs
Market Capitalization
$29.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00
Consensus Rating
Hold

Company Overview

Allakos Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ALLK MarketRank™: 

Allakos scored higher than 62% of companies evaluated by MarketBeat, and ranked 388th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Allakos has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Allakos has received no research coverage in the past 90 days.

  • Read more about Allakos' stock forecast and price target.
  • Earnings Growth

    Earnings for Allakos are expected to grow in the coming year, from ($1.17) to ($0.56) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Allakos is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Allakos has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Allakos' valuation and earnings.
  • Short Interest

    There is no current short interest data available for ALLK.
  • Dividend Yield

    Allakos does not currently pay a dividend.

  • Dividend Growth

    Allakos does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for ALLK.
  • Search Interest

    1 people have searched for ALLK on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Allakos insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    16.12% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    84.64% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Allakos' insider trading history.
Receive ALLK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter.

ALLK Stock News Headlines

Allakos And 2 Other Promising Penny Stocks To Watch
[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
Allakos to Be Acquired for 33 Cents a Share
See More Headlines

ALLK Stock Analysis - Frequently Asked Questions

Allakos' stock was trading at $1.21 on January 1st, 2025. Since then, ALLK shares have decreased by 72.8% and is now trading at $0.3291.

Allakos Inc. (NASDAQ:ALLK) issued its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01.

Allakos (ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Shares of ALLK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Allakos investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE), Arista Networks (ANET), Jabil (JBL) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/06/2024
Today
7/10/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALLK
CIK
1564824
Fax
N/A
Employees
190
Year Founded
N/A

Price Target and Rating

High Price Target
$3.00
Low Price Target
$1.00
Potential Upside/Downside
+507.7%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$185.70 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-140.87%
Return on Assets
-86.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.08
Quick Ratio
6.08

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.93 per share
Price / Book
0.17

Miscellaneous

Outstanding Shares
90,377,000
Free Float
74,942,000
Market Cap
$29.74 million
Optionable
Optionable
Beta
0.15
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:ALLK) was last updated on 7/11/2025 by MarketBeat.com Staff
From Our Partners